Moosey, this is what has happened since 2014…..
Annual Report 2015
PolyNovo’s focus over the next twelve months will be to…
advance our Bone Void Filler agreement with Smith & Nephew towards a commercial application.
Annual Report 2016
Whilst PolyNovo has an agreement with Smith & Nephew for the use of the bone void filler in orthopaedic applications, this has not progressed in the past year. Smith & Nephew remains interested in developing the product within the orthopaedic applications and PolyNovo will pursue advancement of this licence.
Annual Report, 2017
PolyNovo has a licence agreement with Smith & Nephew for the use of NovoSorb two-part polymer for bone void filler in orthopaedic applications. Smith & Nephew have not progressed this product through the commercial phase and we will review the status of this agreement in due course.
Annual Report, 2018
PolyNovo has a licence agreement with Smith & Nephew for the use of NovoSorb two-part polymer for bone void filler in orthopaedic applications. Smith & Nephew have not progressed this product through the commercial phase and we will review the status of this agreement in due course.
It’s an unfortunately all-too-familiar story when very small companies deal with very big companies.
S & N’s loss, I say.
Ann: Appendix 3B Leon Hoare, page-8
-
- There are more pages in this discussion • 15 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PNV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.55 |
Change
-0.030(1.16%) |
Mkt cap ! $1.760B | |||
| Open | High | Low | Value | Volume |
| $2.60 | $2.61 | $2.55 | $1.647M | 639.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 847 | $2.55 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.56 | 3376 | 1 |
View Market Depth
| Last trade - 16.10pm 20/08/2024 (20 minute delay) ? |
| PNV (ASX) Chart |